COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients

Expert Rev Mol Med. 2022 Mar 15:24:e13. doi: 10.1017/erm.2022.10.


Coronavirus disease 2019 (COVID-19) is associated with autoimmunity and systemic inflammation. Patients with autoimmune rheumatic and musculoskeletal disease (RMD) may be at high risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this review, based on evidence from the literature, as well as international scientific recommendations, we review the relationships between COVID-19, autoimmunity and patients with autoimmune RMDs, as well as the basics of a multisystemic inflammatory syndrome associated with COVID-19. We discuss the repurposing of pharmaceutics used to treat RMDs, the principles for the treatment of patients with autoimmune RMDs during the pandemic and the main aspects of vaccination against SARS-CoV-2 in autoimmune RMD patients.

Keywords: Autoimmunity; COVID-19; SARS-CoV-2; drug repurposing; multisystemic inflammatory syndrome; rheumatic and musculoskeletal diseases; vaccination.

Publication types

  • Review

MeSH terms

  • Autoimmunity
  • COVID-19 Drug Treatment*
  • COVID-19* / complications
  • Humans
  • Inflammation
  • Musculoskeletal Diseases* / therapy
  • SARS-CoV-2